VectorY combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions for large disease areas of high unmet medical need.

By combining state-of-the-art technologies and novel and scientific concepts, VectorY’s mission is to bring innovative therapies to patients worldwide.

Founded in August 2020, and based in the Amsterdam Science Park, VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics such as vectorized antibodies for both CNS and somatic disorders, with a special focus on muscle diseases.

With R&D and manufacturing facilities in Amsterdam, VectorY develops proprietary & partnered programs based on its novel AAV-based vectorized antibody & gene therapy platform. Product candidates are based on new vector technologies, which will enable the next generation of highly scalable manufacturing processes within VectorY’s own manufacturing facilities. Our manufacturing capabilities will include a state-of-the-art multi-product GMP facility in the Netherlands, with the capability to deliver suspension based AAV viral vector manufacturing of up to 2000L for both clinical and commercial supply.

Benhamou Global Ventures

Eli Lilly & Company Foundation

Forbion Capital Partners

VectorY

Next to the great news about the $138 million raise for VectorY, we also have other news! 

VectorY welcomes Joachim Witjens in his new role as junior finance specialist. 

Glad to have you in our team Joachim. Good luck! 

#VectorY #genetherapy #newemployee #VectorYan #ALS #Biotech #innovation #neurodegenerativediseases

Today, we announced the raise of €129 Million ($138 Million) in a series A financing round which will be instrumental in supporting the clinical development of VTx-002, targeting TDP-43 for the treatment of ALS.
 
We will also be using the proceeds to accelerate development of the vectorized antibody platform and additional pipeline programs targeting proteinopathies that cause other neurodegenerative diseases.
 
The round was one of the largest private biotech financings in Europe in 2023.
 
Our CEO, Sander van Deventer, commented:
“The Series A financing, supported by such a strong syndicate of European and US investors, is an endorsement of our pioneering approach, world-class team and commitment to bring much-needed therapies to patients with
neurodegenerative diseases.”
 
#VectorY #GeneTherapy #neurodegeneration #biotechnology #financing #LifeSciences #biotech #innovation
 
Read the full news update: https://lnkd.in/ee2mEYxQ

Last week our new DSP scientist Mariana São Pedro started at VectorY.

We are delighted to welcome her as a new VectorYan.

Good luck Mariana!

A very warm welcome to our new intern and VectorYan Daan van den Burg. 

Good luck Daan!

#VectorY #internship #graduates

VectorY is hiring!

Check out our USP scientist vacancy and join our dynamic team of scientists, technicians and other professionals who are focused on developing the best vectorized antibody treatments for patients.

https://lnkd.in/e65UeUYp

A great opportunity for a Technology Transfer Specialist who is going to support the process transfer activities from VectorY R&D to an external GMP manufacturing facility as well as overseeing the GMP operations.

Check out: https://lnkd.in/ew-kNuii

#VectorY #technologytransfer #vacancy #genetherapy #biotech #Amsterdam #GMP #technologytransferspecialist

Great opportunity for an USP Scientist!
This is your chance to join VectorY in our mission to bring innovation therapies to patients worldwide!

https://lnkd.in/e65UeUYp

#USP #Scientist #VectorY #ProcessDevelopment #vacancy #Amsterdam #SciencePark #PhD #career #PDteam

Today we are very pleased to welcome our new scientist Vectorized Antibody Therapy; Alessandro Moro. 

Great to have you in our team Alessandro!

We are looking for an Bioanalytical Laboratory Technician: great chance to be part of our journey!

https://lnkd.in/ek3mvu75

#technician #VectorY #genetherapy #biotech #assay #assaydevelopment
#career #vacancy #opportunity #ALS #assayexecution

They did it!

Last weekend these sportive VectorYans run the ‘Dam to Dam loop’.  We are proud!

Ross Patterson 
Linda Borst 
Jelmer Willems 
Margreet van Beek

rAAV vectors are gene therapy delivery tools used for the treatment of neurodegenerative diseases.

Recombinant Adeno-Associated Virus (rAAV) Vectors

Physical and chemical systems used to deliver therapeutic genes to cells without the need of a viral vector.

Non-Viral Vectors

Clinical trials have used viral vectors such as AAVs, lentivirus, Adv, and retroviruses to carry therapeutic genes for neurodegenerative diseases.

Viral Vectors (AAVs, Lentivirus, Adv, Retroviruses)

Therapeutic strategies targeting neurodegenerative disorders using precision medicine approaches.

Precision Medicine Therapeutic Strategies

VectorY is a biotech company that develops vectorized antibody treatments for neurodegenerative diseases, aiming to enable longer, better lives.

Chief Executive Officer

Operating Partner

co-owner ViskerCycles

Chief Technology Officer

Chief Scientific Officer

Professor

Professor and Chairman Gastroenterology and Hepatology

Professor and Chairman Experimental Medicine

scientist

Next generation gene therapies for neurodegenerative diseases

Sander Deventer

Head Assay Development

Senior Scientist

Scientist

Viroloog/Postdoctoraal onderzoeker

Viroloog/PhD Student

Head Assay Development at VectorY

Adriaan Wilde

Head of Vector Generation

Associate Director Viral Vector & Vaccine Development

Production Manager

Project manager R&D

Senior Postdoctoral Scientist Molecular Virology

Postdoctoral Scientist Molecular Virology

Visiting PhD-student

Research associate

Hilde Tongeren

Consultant Medical Director

Chief Medical Officer

Medical Director

Medical Consultant

Head of Global Medical Affairs a.i.

Vice President Clinical Development

Research Physician

Physician, research fellow, senior registrar

Chief Medical Officer | Orphan and Neuro-degenerative diseases | Gene therapy | Clinical development strategy | Medical affairs | Leadership | Translational medicine

Claus Sundgreen

Principal Scientist, Group Head, Vector Technologies

Head of services

Research And Development Scientist

Research scientist

Ph.D

Giulia Sabbata

Head BioProcess Development , Next generation therapeutics

Sr Scientist, BioProcess Development

Research Associate

PhD in Biochemistry

Master Thesis 2

Master Thesis 1

Summer Intern

Head BioProcess Development , Next generation therapeutics at VectorY

Pranav Puri

Vice President Research

Senior Director New Therapeutic Targets Discovery

Director New Therapeutic Targets Discovery

Scientist RNAi

Scientist R&D

Chief Scientific Officer at VectorY

Pavlina Konstantinova

Director of Antibody Technology

Head of Antibody Technology

Instructor

Director of Antibody Technology @ VectorY | Co-inventor, Advanced Immunology

Wouter Pos

Venture Partner

Chief Corporate Officer

Board Observer

Chief Business Officer

Global Head Oncology Business Development

Vice President Corporate Business Development

Senior Director Corporate Business Development

Director Business Development

Senior associate Business Development

Venture Partner at BGV/ CCO at VectorY

Elena Ritsou

BGV (BioGeneration Ventures)

VP Vector Development

Head of Vector Development

Senior Scientist Viral Vaccines

Junior Scientist (PhD Student) Molecular Virology

Technician Vector Generation

Topmaster student

Co-founder & CTO at VectorY

Barbara Sanders

Chief Financial Officer

Vice President - Healthcare Investment Banking

Analyst - Healthcare Corporate & Investment Banking

Chief Financial Officer at VectorY

Michael Wyzga

Director PD

Head of Process Development

Project Director

Project Manager

Team Leader Cell Line Development

Ph.D.

Director PD at VectorY

Femke Hoeksema

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	May 6, 2024 7:49 AM	6a6e103e
public peers	general	May 6, 2024 7:49 AM	b49d77ad
news daily refresh	general	Jul 25, 2024 12:00 PM	d2220e61
news processing daily refresh	general	May 21, 2024 2:53 AM	7161d9f3
news impact assignment daily	general
news processing basic	general	May 6, 2024 7:49 AM	6527ce60
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	May 6, 2024 7:49 AM	7f11e60f
translate crunchbase fundingrounds	general
peers	general
news basic	general	May 6, 2024 7:49 AM	e81d25a6
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:VECTORYTX

VectorY